Zymeworks Q1 Revenue of $105.4M Beats Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2026
0mins
Reports Q1 revenue $105.4M, consensus $103.66M. "Strong product revenue in the first quarter was driven by continued robust demand for ZORYVE, which remains the leading prescribed branded topical across its three approved indications. During the quarter, we also advanced our pipeline with the initiation of a Phase 1 trial for ARQ-234, our biologic candidate for atopic dermatitis, submission of an sNDA to the FDA to expand the ZORYVE cream indication in atopic dermatitis to patients as young as 3 months, and progress on our Phase 2 proof-of-concept studies of ZORYVE in potential new indications," said Frank Watanabe, president and chief executive officer. "We also continued to generate positive cash flow, underscoring our focus on financial and operational discipline as we continue to advance our corporate strategy."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARQT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARQT
Wall Street analysts forecast ARQT stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 26.070
Low
30.00
Averages
32.00
High
37.00
Current: 26.070
Low
30.00
Averages
32.00
High
37.00
About ARQT
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company develops therapies against biologically validated targets and produces a pipeline for a range of inflammatory dermatological conditions. Its portfolio consists of topical and systemic treatments to treat immune-mediated dermatological diseases and conditions. Its product portfolio includes ZORYVE Roflumilast Cream, ZORYVE Roflumilast Foam, and ARQ-234. The ZORYVE Roflumilast Cream is used for the treatment of seborrheic dermatitis in individuals aged 9 years and older. The ZORYVE Roflumilast Foam for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older. The ARQ-234 is a fusion protein that is a checkpoint agonist of the CD200 Receptor (CD200R). CD200R is an immune-regulatory receptor which is an immunological checkpoint with a role in the maintenance of immune tolerance.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Comparative Analysis of Arcutis and Vertex Biotherapeutics
- Significant Revenue Growth: Arcutis Biotherapeutics reported nearly $376.1 million in revenue for FY 2025, marking a 101% increase year-over-year, despite a net loss of $16.1 million, which is a substantial improvement from the previous year's $140 million loss, indicating effective revenue scaling.
- Market Competition Pressure: Arcutis relies heavily on its Zoryve product line to disrupt the competitive dermatology market, yet faces formidable competition from giants like AbbVie and Pfizer, along with ongoing patent litigation with Teva Pharmaceuticals, where failure to protect intellectual property could severely impact operations.
- Vertex's Market Dominance: Vertex Pharmaceuticals achieved $12 billion in revenue for FY 2025, reflecting a nearly 10% year-over-year increase, and reported a net income of approximately $4 billion with a net margin of about 32.7%, showcasing its strong profitability and market position in rare disease treatments.
- R&D Investment and New Markets: Vertex is heavily investing in R&D to expand its cystic fibrosis drug market coverage and has received accelerated approval for povetacicept in IgA nephropathy, which could become a blockbuster drug, further solidifying its leadership in the market.
See More
Investment Comparison: Arcutis vs. Vertex
- Financial Performance Comparison: Arcutis Biotherapeutics achieved nearly $376.1 million in revenue for FY 2025, marking a 101% year-over-year growth, although it reported a net loss of $16.1 million, which is a significant improvement from the previous year's $140 million loss, indicating progress in revenue growth and cost management.
- Market Position Analysis: Vertex Pharmaceuticals generated $12 billion in revenue for FY 2025, with a net income of nearly $4 billion and a net margin of approximately 32.7%, reflecting its strong market position and profitability in the rare disease treatment sector.
- Risk Assessment: Arcutis faces competitive pressure from giants like AbbVie and Pfizer, alongside patent litigation with Teva, which could significantly impact operations if intellectual property is not protected; Vertex, on the other hand, is vulnerable to pricing pressures due to its heavy revenue concentration in cystic fibrosis drugs.
- Future Outlook: Arcutis is projected to achieve positive cash flow in FY 2026 with a 26% revenue increase to $497 million, despite seasonal demand fluctuations; Vertex is expected to expand its cystic fibrosis drug market, with sales anticipated to exceed $13 billion, showcasing strong growth potential.
See More
Arcutis Launches Virtual Health Platform for Dermatology Care
- Launch of Virtual Health Platform: On June 30, 2026, Arcutis Biotherapeutics introduced a new virtual health platform aimed at providing additional care pathways for over 45 million Americans suffering from eczema, seborrheic dermatitis, and plaque psoriasis, significantly enhancing patient access to dermatological care.
- Connecting Independent Dermatologists: The platform connects patients with independent, board-certified dermatologists through a streamlined digital experience, facilitating timely evaluations and treatment recommendations for those who have not yet seen a dermatologist, thereby reducing delays caused by long wait times.
- Promotion of ZORYVE® Products: The platform is designed to expand access to the ZORYVE (roflumilast) portfolio, enabling patients to better understand their treatment options while receiving appropriate care, further driving the company's market share in the dermatology sector.
- Enhancing Patient Experience: Arcutis emphasizes that the virtual health platform complements traditional dermatology visits by addressing geographic limitations and scheduling challenges, helping more patients access the specialized treatment they need, reflecting the company's commitment to improving care for individuals with chronic inflammatory skin diseases.
See More
Arcutis Receives FDA Approval for ZORYVE in Children
- FDA Approval for Expanded Indication: Arcutis Biotherapeutics announced that its ZORYVE (roflumilast) cream 0.3% has received FDA approval, becoming the first non-steroidal topical treatment for plaque psoriasis in children as young as 2, marking a significant breakthrough in pediatric psoriasis care.
- Significant Market Potential: With psoriasis affecting approximately 9 million people in the U.S., the approval of ZORYVE opens access to this large market, expected to drive future sales growth, particularly among pediatric patients.
- Clinical Research Support: The approval is based on a 4-week Maximal Usage Systemic Exposure (MUSE) study in children aged 2 to 5, demonstrating ZORYVE's safety and efficacy in improving psoriasis symptoms, thereby enhancing the product's competitive position in the market.
- Notable Sales Growth: In Q1 2026, ZORYVE sales reached $105.39 million, a 65% increase from the previous year, with $32.7 million from the 0.3% cream, indicating strong market demand and the company's growth potential in the biopharmaceutical sector.
See More
FDA Approves ZORYVE Cream for Children as Young as 2 for Plaque Psoriasis
- FDA Approval for New Indication: ZORYVE cream 0.3% has received FDA approval as the first non-steroidal treatment for children aged 2 and older with plaque psoriasis, addressing a significant treatment gap and expected to greatly improve the quality of life for young patients.
- Safety and Efficacy: Clinical studies demonstrate that ZORYVE cream is safe and well-tolerated in children aged 2 to 5 years, with no restrictions on duration of use, providing physicians and caregivers with a flexible treatment option that reduces reliance on steroids.
- Meeting Market Demand: The approval is based on a 4-week Maximal Usage Systemic Exposure study, showing efficacy in children comparable to adults, which is expected to drive Arcutis's further penetration into the pediatric dermatology market, fulfilling the urgent need for effective treatments among parents.
- Strategic Advancement: This marks the seventh FDA approval for ZORYVE in four years, highlighting Arcutis's commitment to innovation in pediatric dermatology, which is anticipated to enhance its market competitiveness and increase brand recognition.
See More
Analysis of Arcutis Biotherapeutics Executive Stock Transaction
- Executive Stock Sale: Sue-Jean Lin, a director at Arcutis Biotherapeutics, sold 4,946 shares of common stock on June 15, 2026, for a total value of $121,000, reducing her direct holdings from 32,513 shares to 27,567 shares, which reflects her ongoing confidence in the company's future.
- Transaction Plan Context: This sale was executed under a 10b5-1 trading plan adopted on December 4, 2025, indicating that it was a pre-arranged, routine disposition rather than discretionary selling, showcasing executive transparency and compliance.
- Company Financial Performance: As of June 15, 2026, Arcutis had a market capitalization of $3.28 billion, with a 1-year price increase of 89.65%, and its ZORYVE product line saw a 65% year-over-year increase in net revenue to $105.4 million in Q1, indicating strong market demand and growth potential.
- Future Outlook: Although Lin's stake was reduced by about 15%, she still holds over 27,500 shares, maintaining significant exposure to Arcutis' future performance, with the company guiding for full-year revenues between $480 million and $495 million, indicating sustainable profitability prospects.
See More
Comparative Analysis of Arcutis and Vertex Biotherapeutics
- Significant Revenue Growth: Arcutis Biotherapeutics reported nearly $376.1 million in revenue for FY 2025, marking a 101% increase year-over-year, despite a net loss of $16.1 million, which is a substantial improvement from the previous year's $140 million loss, indicating effective revenue scaling.
- Market Competition Pressure: Arcutis relies heavily on its Zoryve product line to disrupt the competitive dermatology market, yet faces formidable competition from giants like AbbVie and Pfizer, along with ongoing patent litigation with Teva Pharmaceuticals, where failure to protect intellectual property could severely impact operations.
- Vertex's Market Dominance: Vertex Pharmaceuticals achieved $12 billion in revenue for FY 2025, reflecting a nearly 10% year-over-year increase, and reported a net income of approximately $4 billion with a net margin of about 32.7%, showcasing its strong profitability and market position in rare disease treatments.
- R&D Investment and New Markets: Vertex is heavily investing in R&D to expand its cystic fibrosis drug market coverage and has received accelerated approval for povetacicept in IgA nephropathy, which could become a blockbuster drug, further solidifying its leadership in the market.
See More
Investment Comparison: Arcutis vs. Vertex
- Financial Performance Comparison: Arcutis Biotherapeutics achieved nearly $376.1 million in revenue for FY 2025, marking a 101% year-over-year growth, although it reported a net loss of $16.1 million, which is a significant improvement from the previous year's $140 million loss, indicating progress in revenue growth and cost management.
- Market Position Analysis: Vertex Pharmaceuticals generated $12 billion in revenue for FY 2025, with a net income of nearly $4 billion and a net margin of approximately 32.7%, reflecting its strong market position and profitability in the rare disease treatment sector.
- Risk Assessment: Arcutis faces competitive pressure from giants like AbbVie and Pfizer, alongside patent litigation with Teva, which could significantly impact operations if intellectual property is not protected; Vertex, on the other hand, is vulnerable to pricing pressures due to its heavy revenue concentration in cystic fibrosis drugs.
- Future Outlook: Arcutis is projected to achieve positive cash flow in FY 2026 with a 26% revenue increase to $497 million, despite seasonal demand fluctuations; Vertex is expected to expand its cystic fibrosis drug market, with sales anticipated to exceed $13 billion, showcasing strong growth potential.
See More
Arcutis Launches Virtual Health Platform for Dermatology Care
- Launch of Virtual Health Platform: On June 30, 2026, Arcutis Biotherapeutics introduced a new virtual health platform aimed at providing additional care pathways for over 45 million Americans suffering from eczema, seborrheic dermatitis, and plaque psoriasis, significantly enhancing patient access to dermatological care.
- Connecting Independent Dermatologists: The platform connects patients with independent, board-certified dermatologists through a streamlined digital experience, facilitating timely evaluations and treatment recommendations for those who have not yet seen a dermatologist, thereby reducing delays caused by long wait times.
- Promotion of ZORYVE® Products: The platform is designed to expand access to the ZORYVE (roflumilast) portfolio, enabling patients to better understand their treatment options while receiving appropriate care, further driving the company's market share in the dermatology sector.
- Enhancing Patient Experience: Arcutis emphasizes that the virtual health platform complements traditional dermatology visits by addressing geographic limitations and scheduling challenges, helping more patients access the specialized treatment they need, reflecting the company's commitment to improving care for individuals with chronic inflammatory skin diseases.
See More
Arcutis Receives FDA Approval for ZORYVE in Children
- FDA Approval for Expanded Indication: Arcutis Biotherapeutics announced that its ZORYVE (roflumilast) cream 0.3% has received FDA approval, becoming the first non-steroidal topical treatment for plaque psoriasis in children as young as 2, marking a significant breakthrough in pediatric psoriasis care.
- Significant Market Potential: With psoriasis affecting approximately 9 million people in the U.S., the approval of ZORYVE opens access to this large market, expected to drive future sales growth, particularly among pediatric patients.
- Clinical Research Support: The approval is based on a 4-week Maximal Usage Systemic Exposure (MUSE) study in children aged 2 to 5, demonstrating ZORYVE's safety and efficacy in improving psoriasis symptoms, thereby enhancing the product's competitive position in the market.
- Notable Sales Growth: In Q1 2026, ZORYVE sales reached $105.39 million, a 65% increase from the previous year, with $32.7 million from the 0.3% cream, indicating strong market demand and the company's growth potential in the biopharmaceutical sector.
See More
FDA Approves ZORYVE Cream for Children as Young as 2 for Plaque Psoriasis
- FDA Approval for New Indication: ZORYVE cream 0.3% has received FDA approval as the first non-steroidal treatment for children aged 2 and older with plaque psoriasis, addressing a significant treatment gap and expected to greatly improve the quality of life for young patients.
- Safety and Efficacy: Clinical studies demonstrate that ZORYVE cream is safe and well-tolerated in children aged 2 to 5 years, with no restrictions on duration of use, providing physicians and caregivers with a flexible treatment option that reduces reliance on steroids.
- Meeting Market Demand: The approval is based on a 4-week Maximal Usage Systemic Exposure study, showing efficacy in children comparable to adults, which is expected to drive Arcutis's further penetration into the pediatric dermatology market, fulfilling the urgent need for effective treatments among parents.
- Strategic Advancement: This marks the seventh FDA approval for ZORYVE in four years, highlighting Arcutis's commitment to innovation in pediatric dermatology, which is anticipated to enhance its market competitiveness and increase brand recognition.
See More
Analysis of Arcutis Biotherapeutics Executive Stock Transaction
- Executive Stock Sale: Sue-Jean Lin, a director at Arcutis Biotherapeutics, sold 4,946 shares of common stock on June 15, 2026, for a total value of $121,000, reducing her direct holdings from 32,513 shares to 27,567 shares, which reflects her ongoing confidence in the company's future.
- Transaction Plan Context: This sale was executed under a 10b5-1 trading plan adopted on December 4, 2025, indicating that it was a pre-arranged, routine disposition rather than discretionary selling, showcasing executive transparency and compliance.
- Company Financial Performance: As of June 15, 2026, Arcutis had a market capitalization of $3.28 billion, with a 1-year price increase of 89.65%, and its ZORYVE product line saw a 65% year-over-year increase in net revenue to $105.4 million in Q1, indicating strong market demand and growth potential.
- Future Outlook: Although Lin's stake was reduced by about 15%, she still holds over 27,500 shares, maintaining significant exposure to Arcutis' future performance, with the company guiding for full-year revenues between $480 million and $495 million, indicating sustainable profitability prospects.
See More
